made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study. Justin Tallis/AFP via Getty Images hide caption
A third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study.
Justin Tallis/AFP via Getty ImagesA third COVID-19 vaccine could receive emergency use authorization from the Food and Drug Administration this month. The vaccine made by Johnson & Johnson is 66% effective in preventing moderate to severe disease, according to a global study.
Combined with the two vaccines currently in circulation, the U.S. could have three vaccines that are all highly effective at preventing death or hospitalization due to COVID-19.
Despite that promising news, NPR's Richard Harris reports on why the journey to herd immunity still won't be easy.
And Rae Ellen Bichelle goes inside a Colorado long-term care facility that has vaccinated nearly all of its residents. They say the initial steps to a return to normalcy feel great.
Email us at
This episode was produced by Brianna Scott, Lee Hale and Brent Baughman. It was edited by Sami Yenigun with help from Joe Neel, Scott Hensley, and Wynne Davis. Additional reporting from NPR's Allison Aubrey. Our executive producer is Cara Tallo.